ArticleResearch and reports in urology2025
Radiation Therapy for Local or Biochemical Recurrence Following Radical Prostatectomy in Patients with Prostate Cancer.
Article in Research and reports in urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction and Objectives: To investigate outcomes of patients with biochemical or local recurrence, without distant metastasis, who received radiation therapy targeting the prostate bed at our hospital following radical prostatectomy for prostate cancer. Methods: Patients suspected of recurrence after radical prostatectomy, indicated by an increase in PSA levels or other factors, were evaluated through imaging tests for local recurrence and distant metastasis. Those who showed no local recurrence received salvage radiotherapy to the prostate bed at a dose of 64.8 Gy. Patients with local recurrence received radiotherapy of 70.8 Gy to the site of local recurrence and 64.8 Gy to the prostate bed. Results: Among 19 cases of local recurrence following radical prostatectomy, three out of nine patients who did not receive ADT experienced recurrence after local radiation therapy. In contrast, none of the ten patients who received ADT during radiation therapy experienced recurrence following treatment. No significant difference was observed in clinical recurrence-free survival between patients receiving radiation therapy alone and those receiving ADT during radiation therapy. (p = 0.302) Fifty-six of the 57 patients without local recurrence were evaluated regarding their PSA doubling time (PSADT). Those with a PSADT of 6 months or more at the time of recurrence following radical prostatectomy tended to show longer clinical recurrence-free survival after local radiation therapy compared with showing PSADT of less than 6 months. (p=0.06) Patients with local recurrence who were treated with escalated radiation doses did not show any difference in the incidence of radiotherapy-related gastrointestinal toxicity compared with patients without local recurrence. Conclusion: Although this study was conducted at a single institution with a small sample size and a limited number of patients, ADT may be beneficial in preventing recurrence following radiation therapy for local recurrence after radical prostatectomy. When considering salvage radiation therapy for patients with biochemical recurrence following radical prostatectomy, PSADT may be useful.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.